AR035422A1 - Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. - Google Patents
Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.Info
- Publication number
- AR035422A1 AR035422A1 ARP020100261A ARP020100261A AR035422A1 AR 035422 A1 AR035422 A1 AR 035422A1 AR P020100261 A ARP020100261 A AR P020100261A AR P020100261 A ARP020100261 A AR P020100261A AR 035422 A1 AR035422 A1 AR 035422A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- lower alkyl
- hydrogen
- phenyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Abstract
Compuestos derivados de imidazol de fórmula general 1 en donde A es fenilo, piridin-2-ilo, piridin-3-ilo, o piperidin-1-ilo; R1 y R2 son independientemente el uno del otro hidrógeno, halógeno, alquilo inferior, cicloalquilo, alquenilo inferior, trifluoro-metilo, -O-trifluorometilo, S-trifluorometilo, S-alquilo inferior, alcoxilo inferior, -CHF2, -C(alquilo inferior)F2, -OCHF2, fenilo, nitro, benciloxilo, hidroxilo o amino o son junto a los átomos de carbono a los que están unidos en cualquiera de las composiciones adyacentes -CH=CH-CH=CH-, -CH=CH-CH=N-, -(CH2)3-, -O-CH2-O-, -O-CF2-O-, -CH2-O-CH2-, CH2CH2-O-; R3 es hidrógeno, alquilo inferior, cicloalquilo, fenilo, S-alquilo inferior, amino, alquilo inferior-amino, -NHC(O)-alquilo inferior o hidroxi-alquilo inferior; R4 y R5 son independientemente el uno del otro hidrógeno o alquilo inferior o son junto al átomo de carbono a los que están unidos -(CH2)4-; R6 y R6' son independientemente el uno del otro hidrógeno o alquilo inferior; X es -N< o; Y es =N-, -NH-, -N=CH- o -CH=; Z es -CR7=, -N=, -NR7-, -N=CR7-, =CH-N=C(R7)- o =N-CH=CH-; R7 es hidrógeno, -CH2OH o alquilo inferior; n es 0, 1 o 2: m es 0 o 1; y la línea punteada puede ser un enlace; y las sales de adicción ácida farmacéuticamente aceptables de los mismos. Estos compuestos poseen una buena afinidad a los bloqueadores selectivos de un subtipo de receptor de NMDA (N-metil-D-aspartato), que posee una función clave en la modulación de la actividad neuronal y plasticidad que lo hace desarrollar un papel clave en la mediación de procesos subyacentes al desarrollo del SNC tanto como en el aprendizaje y la formación de la memoria. Estos compuestos son por lo tanto adecuados en el control o tratamiento de enfermedades, relacionadas a este receptor. Un medicamento que contiene uno o más de los compuestos, un proceso para la preparación de los compuestos y el uso de los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01101947 | 2001-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035422A1 true AR035422A1 (es) | 2004-05-26 |
Family
ID=8176317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100261A AR035422A1 (es) | 2001-01-29 | 2002-01-25 | Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6610723B2 (es) |
| EP (1) | EP1358165B1 (es) |
| JP (1) | JP4094956B2 (es) |
| KR (1) | KR100619106B1 (es) |
| CN (2) | CN1489580B (es) |
| AR (1) | AR035422A1 (es) |
| AT (1) | ATE425147T1 (es) |
| BR (1) | BR0206758A (es) |
| CA (1) | CA2434813C (es) |
| CY (1) | CY1110265T1 (es) |
| DE (1) | DE60231477D1 (es) |
| DK (1) | DK1358165T3 (es) |
| ES (1) | ES2319967T3 (es) |
| GC (1) | GC0000318A (es) |
| GT (1) | GT200200013A (es) |
| HK (2) | HK1063794A1 (es) |
| JO (1) | JO2292B1 (es) |
| MX (1) | MXPA03006773A (es) |
| MY (1) | MY138334A (es) |
| PA (1) | PA8537801A1 (es) |
| PE (1) | PE20020917A1 (es) |
| PT (1) | PT1358165E (es) |
| WO (1) | WO2002060877A1 (es) |
| ZA (1) | ZA200305626B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2485093A1 (en) * | 2002-05-02 | 2003-11-13 | Neurogen Corporation | Substituted imidazole derivatives: gabaa receptor ligands |
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| KR101170925B1 (ko) * | 2004-06-18 | 2012-08-07 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물 |
| ITRM20050094A1 (it) * | 2005-03-04 | 2006-09-05 | Univ Siena | Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari. |
| US7939556B2 (en) | 2005-10-14 | 2011-05-10 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| CA2687973C (en) * | 2007-05-23 | 2015-04-07 | Allergan, Inc. | ((bicylicheteroaryl) imidazolyl)methylheteroaryl compounds as adrenergic receptor agonists |
| WO2010009327A1 (en) | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
| KR20110092266A (ko) | 2008-08-04 | 2011-08-17 | 씨에이치디아이 파운데이션, 인코포레이티드 | 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법 |
| MX2012008346A (es) | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos. |
| US8993743B2 (en) | 2010-02-18 | 2015-03-31 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Chimeric surface active proteins |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| CN106518845B (zh) | 2011-08-30 | 2019-09-13 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
| BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
| JP6105594B2 (ja) * | 2011-09-30 | 2017-03-29 | エンドゥ ファーマシューティカルズ，インコーポレイティド | 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体 |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
| JP6618525B2 (ja) * | 2014-08-15 | 2019-12-11 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | ピラゾール類 |
| DK3180329T3 (da) * | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Triazoler som nr2b receptorinhibitorer |
| SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
| IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| EP3982958A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| EP3983073A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3627155A1 (de) | 1986-08-11 | 1988-02-18 | Schering Ag | Imidazol-derivate |
| CN1040107C (zh) * | 1993-01-02 | 1998-10-07 | 山道士有限公司 | 咪唑基甲基吡啶 |
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| DE19816880A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| DE60007697T2 (de) | 1999-07-21 | 2004-12-09 | F. Hoffmann-La Roche Ag | Triazolderivate |
-
2001
- 2001-12-20 US US10/029,342 patent/US6610723B2/en not_active Expired - Lifetime
-
2002
- 2002-01-21 BR BR0206758-7A patent/BR0206758A/pt not_active IP Right Cessation
- 2002-01-21 MX MXPA03006773A patent/MXPA03006773A/es active IP Right Grant
- 2002-01-21 CN CN028042557A patent/CN1489580B/zh not_active Expired - Fee Related
- 2002-01-21 AT AT02714095T patent/ATE425147T1/de active
- 2002-01-21 ES ES02714095T patent/ES2319967T3/es not_active Expired - Lifetime
- 2002-01-21 CA CA002434813A patent/CA2434813C/en not_active Expired - Fee Related
- 2002-01-21 WO PCT/EP2002/000552 patent/WO2002060877A1/en active IP Right Grant
- 2002-01-21 DK DK02714095T patent/DK1358165T3/da active
- 2002-01-21 EP EP02714095A patent/EP1358165B1/en not_active Expired - Lifetime
- 2002-01-21 JP JP2002561027A patent/JP4094956B2/ja not_active Expired - Fee Related
- 2002-01-21 CN CN2010101215002A patent/CN101798298B/zh not_active Expired - Fee Related
- 2002-01-21 PT PT02714095T patent/PT1358165E/pt unknown
- 2002-01-21 DE DE60231477T patent/DE60231477D1/de not_active Expired - Lifetime
- 2002-01-21 KR KR1020037009992A patent/KR100619106B1/ko not_active IP Right Cessation
- 2002-01-24 PE PE2002000055A patent/PE20020917A1/es not_active Application Discontinuation
- 2002-01-24 PA PA20028537801A patent/PA8537801A1/es unknown
- 2002-01-25 MY MYPI20020294A patent/MY138334A/en unknown
- 2002-01-25 AR ARP020100261A patent/AR035422A1/es not_active Application Discontinuation
- 2002-01-28 GC GCP20021833 patent/GC0000318A/en active
- 2002-01-28 GT GT200200013A patent/GT200200013A/es unknown
- 2002-01-29 JO JO20029A patent/JO2292B1/en active
-
2003
- 2003-02-11 US US10/364,596 patent/US6683097B2/en not_active Expired - Lifetime
- 2003-02-13 US US10/365,995 patent/US6667335B2/en not_active Expired - Lifetime
- 2003-07-21 ZA ZA200305626A patent/ZA200305626B/en unknown
-
2004
- 2004-09-03 HK HK04106638.1A patent/HK1063794A1/xx not_active IP Right Cessation
-
2009
- 2009-05-15 CY CY20091100522T patent/CY1110265T1/el unknown
-
2011
- 2011-01-26 HK HK11100798.1A patent/HK1146646A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035422A1 (es) | Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. | |
| AU2015239886B2 (en) | Indole derivatives for use in medicine | |
| AU2010286569B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| US7091227B2 (en) | Benzothiazole derivatives | |
| RU2515972C2 (ru) | Диазакарбазолы и способы применения | |
| RU2014131390A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ | |
| CN107207474A (zh) | 被取代的杂环作为溴结构域抑制剂 | |
| SG183855A1 (en) | Morpholinylquinazolines | |
| CN102647904A (zh) | 新型三环蛋白激酶调节剂 | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| CN107406438A (zh) | 溴结构域的抑制剂 | |
| TW200621762A (en) | Novel compounds | |
| AR007897A1 (es) | Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. | |
| CN103080093A (zh) | 吲唑化合物及其应用 | |
| TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| CZ2002936A3 (cs) | Pyrazolopyrimidiny jako terapeutické prostředky | |
| AR002971A1 (es) | COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA. | |
| NO20061746L (no) | Kinazolinderivater som antiproliferative midler | |
| NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
| CZ20032858A3 (en) | Pyrazolopyrimidines as therapeutic agents | |
| SG172805A1 (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
| UY28578A1 (es) | Derivados de amida | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| NO20055510L (no) | 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister | |
| JP2022191259A (ja) | キナーゼネットワークの阻害剤およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |